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Abstract: Determination of the targets of a compound re-
mains an essential aspect in drug discovery. A complete un-
derstanding of all binding interactions is critical to recognize
in advance both therapeutic effects and undesired conse-
quences. However, the complete polypharmacology of many
drugs currently in clinical development is still unknown, es-
pecially in the case of G-protein-coupled receptor (GPCR) li-
gands. In this work we have developed a chemoproteomic
platform based on the use of chemical probes to explore
the target profile of a compound in biological systems. As
proof of concept, this methodology has been applied to se-
lected ligands of the therapeutically relevant serotonin 5-
HT1A and 5-HT6 receptors, and we have identified and vali-
dated some of their off-targets. This approach could be ex-
tended to other drugs of interest to study the targeted pro-
teome in disease-relevant systems.
Introduction
In drug discovery, most researchers pursue high affinity for
a single therapeutic target combined with high selectivity, be-
lieving that this will maximize efficacy and minimize side ef-
fects. Indeed, activity at nontherapeutic targets can lead to
toxicity and cause adverse effects, and a number of drugs
have been withdrawn by the pharmaceutical industry for this
reason. However, in recent years, some multitarget drugs have
become unprecedentedly efficacious and safer. In current re-
search, polypharmacology is increasingly being appreciated
since it holds opportunities for drug discovery and drug repur-
posing. In this regard, the identification of the different pro-
teins targeted by a compound has helped to explain mecha-
nisms of action, therapeutic activities, and undesirable side ef-
fects of marketed drugs such as aspirin,[1, 2] thalidomide,[3] dasa-
tinib,[4] or tivantinib,[5] just to name a few examples. Hence, the
development of chemical tools that facilitate the study of poly-
pharmacology for ligands of therapeutically relevant proteins
is of outmost interest and it is attracting much attention.[6]
Among them, chemical probes have emerged as efficacious
tools for global protein profiling. Two different approaches can
be applied depending on the type of probe used. The first
methodology, activity-based protein profiling (ABPP), uses
probes characterized by the presence of an electrophilic group
that will react in a covalent manner with the nucleophile in
the active site of an enzyme. In this manner, the availability of
probes directed towards different enzyme families has facilitat-
ed the throughput identification of enzyme targets across the
proteome.[7] Since this approach is limited to enzymes with
known catalytic mechanisms, alternative methods, based on
the development of metabolite-based probes have emerged.
In this second type of approach, binding to the target is direct-
ed by the affinity of the scaffold and not by intrinsic chemical
reactivity. This methodology has been recently applied to the
identification of the protein targets of different lipid metabo-
lites.[8] In all cases, the chemical probe bears a reporter tag
that enables protein visualization and/or enrichment prior to
mass spectrometry based identification. Considering the po-
tential of chemoproteomic approaches for studying target pro-
files, we wondered whether such a strategy could be applied
to G-protein-coupled receptors (GPCRs) to facilitate the non-
biased profiling of GPCR ligands. Given the importance of
GPCRs as drug targets, specific panels of proteins are common-
ly screened for during the first steps of drug discovery. Howev-
er, this approach is normally restricted to proteins that belong
to the same family (that is, other GPCRs) or proteins with
known sequence similarities. Therefore, the development of
methods aimed at unravelling unexpected interactions and at
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associating these with additional effects (both therapeutic and
non-desired) has attracted intense interest. In this regard, bio-
informatic efforts have contributed to the generation of com-
putational tools for the prediction and identification of unex-
pected off-targets.[9] However, an experimental approach that
facilitates the high-throughput straightforward and non-biased
study of polypharmacology for known ligands of GPCRs is cur-
rently lacking. Toward this end, we have developed a chemo-
proteomic platform based on
the use of chemical probes that
enables the study of the poly-
pharmacology of GPCR ligands.
As proof of concept, this ap-
proach has been used to identify
additional targets of selected se-
rotonin receptor ligands. Among
the different serotonin receptors,
we have focused our attention
on two of them, the clinically va-
lidated 5-HT1A receptor (5-
HT1AR)
[10] and the currently under
validation 5-HT6 receptor (5-
HT6R).
[11] Herein, high-affinity li-
gands of these receptors have
been modified with appropriate
tag(s) for covalent binding and
subsequent enrichment of the
bound proteins followed by
their identification using mass
spectrometry (MS). These recep-
tor-directed probes work in gel-
based assays to enable protein
profiling and they bind their
cognate receptor as well as sev-
eral additional targets in proteo-
mic experiments. In particular,
HSP60 and prohibitin proteins
have been identified as off-tar-
gets of the studied 5-HT1A and 5-
HT6 receptor ligands, respective-
ly. These proteins have been validated and their relevance as-
sessed in cellular systems. This approach could be extended to
other systems to study the proteome targeted by the com-
pound of interest in disease-relevant samples.
Results and Discussion
Design and synthesis of the probes
We reasoned that the probes suitable for chemoproteomic
studies would need to have three general features: 1) a photo-
reactive group for ultraviolet (UV) light-induced cross-linking
to target proteins such as benzophenone; 2) a biotin subunit,
which enables enrichment and subsequent identification of
bound proteins; and 3) a scaffold with affinity for the serotonin
receptor under study that after introduction of the photo-
cross-linking and biotin subunits would still keep the affinity
for the receptor and, by extension, for the rest of the off-tar-
gets (or most of them). Alternatively, the possibility of a smaller
tag such as a terminal alkyne for click chemistry was also con-
sidered. Taking into account these considerations, we designed
two sets of probes starting from high affinity ligands of 5-HT1A
and 5-HT6 receptors (Schemes 1 and 2, respectively). In the
case of the 5-HT1AR, ligand UCM-2550
[12] (1, Ki=2.4 nm,
Scheme 1) was selected.
Previous structure–activity relationship (SAR) studies indicat-
ed that the 7a-position of the bicyclohydantoin could admit
the introduction of a tag without dramatically affecting affini-
ty.[13] Therefore, we explored the possibility of attaching the
biotin moiety at the 7a-position and replacing the naphthalene
ring by benzophenone (compound 2, Scheme 1). Alternatively,
we designed different tags that contain both benzophenone
and biotin or benzophenone and a terminal alkyne, which can
be introduced at the 7a-position of the bicyclohydantoin (com-
pounds 3–7, Scheme 1). These compounds were synthesized
by condensation of the intermediate amines 8–10 with the
corresponding carboxylic acids that contain the different tags
(Scheme 1). With respect to the 5-HT6R, we selected the ligand
developed by SmithKline Beecham SB-271046[14] (13, Ki=
1.2 nm, Scheme 2) as starting point. In this case, we were able
to successfully replace the benzothiophene ring by a benzo-
phenone (compound 14, Ki=1.6 nm, Scheme 2), so we ex-
Scheme 1. Design and synthesis of probes for serotonin 5-HT1AR: a) biotin, DCC, HOBt, DMAP, DMF, RT, 39%; b) 3-
oxo-3-({4-[4-(biotinylamino)benzoyl]phenyl}amino)propanoic acid (11), EDC, HOBt, DMF, DCM, RT, 15–36%; c) 4-
benzoyl-N-biotinyl-l-phenylalanine (12), EDC, HOBt, DMF, DCM, RT, 20-46%; d) Fmoc-4-benzoyl-l-phenylalanine,
EDC, HOBt, DMF, DCM, RT, 80%; e) piperidine, DCM, 0 8C, 75%; f) 5-hexynoic acid, DCC, DMAP, DCM, RT, 53%.
DCC=N,N-dicyclohexylcarbodiimide; DCM=dichloromethane; DMAP=4-dimethylaminopyridine; EDC=N’-(3-di-
methylaminopropyl)-N-ethylcarbodiimide; Fmoc=9-fluorenylmethoxycarbonyl ; HOBt=1-hydroxybenzotriazole.
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plored the most suitable positions (X, Y, and Z) to introduce
the biotin moiety or the terminal alkyne (compounds 15–19,
Scheme 2). The preparation of these compounds started with
benzenesulfonyl chloride 20, which was transformed into the
benzophenone derivative 21 and subsequently alkylated in the
nitrogen of the piperazine (compounds 15 and 19) or in the
nitrogen of the sulfonamide group (compounds 16 and 18).
Alternatively, reaction of 20 with N-[3-(3-aminobenzoyl)phe-
nyl]biotinamide (26) yielded, after deprotection of the trichlor-
oacetyl group, final compound 17 (Scheme 2). All the final
compounds were tested for affinity at the corresponding re-
ceptor by binding assays (Table 1). The results indicate that for
5-HT1AR, the use of one tag that contains both groups (biotin
and benzophenone) is more favorable in terms of affinity, as
shown by the Ki values obtained for compounds 3–7 [Ki (5-
HT1A)=1.1-5 nm] when compared to derivative 2 [Ki (5-HT1A)=
76 nm] . In the case of 5-HT6R, the introduction of the biotin
moiety [Ki (16, 5-HT6)=94 nm] or the terminal alkyne [Ki (18, 5-
HT6)=95 nm] in the sulfonamide allowed us to obtain probes
with affinity for this receptor. Taking into account these data,
probes 5 and 16, with the best affinity values for 5-HT1A and 5-
HT6 receptors, respectively, were selected for the proteomic ex-
periments.
Scheme 2. Design and synthesis of probes for serotonin 5-HT6R: a) 3-aminobenzophenone, pyridine, DCM, RT, 65%; b) 1m aq. KOH, THF, RT, 76–98%; c) tert-
butyl 6-bromohexylcarbamate, NaI, DMF, 80 8C, 67%; d) TFA, DCM, RT, 91–95%; e) biotin, EDC, HOBt, DMF, DCM, RT, 58–82%; f) 4-bromobutyne, NaI, DMF,
80 8C, 47%; g) tert-butyl 6-bromohexylcarbamate or tert-butyl 2-bromoethylcarbamate, Cs2CO3, DMF, RT, 74–81%; h) 5-hexynoic acid, DCC, DMAP, DCM, RT,
61%; i) N-[3-(3-aminobenzoyl)phenyl]biotinamide (26), pyridine, DMF, DCM, RT, 51%. TFA= trifluoroacetic acid.
Table 1. Binding affinities of synthesized probes 1–7, 13–19, 27, and 28.
Cpd 5-HT1A Ki (nm
)[a] Cpd 5-HT6 Ki (nm)
[a]
1 2.4[b] 13 1.2[c]
2 765 14 1.60.1
3 2.70.3 15 >1000
4 41 16 947
5 1.10.5 17 >1000
6 52 18 955
7 51 19 38017
27 226 28 891
[a] Ki values are the mean standard error from three independent ex-
periments performed in triplicate. [b] Value from reference [12] . [c] Value
from reference [14] .
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Gel profiling of cell membranes
Before setting up the proteomic platform, it was necessary to
confirm that the compounds were actually able to label pro-
teins specifically, that is, in an irradiation- and dose-dependent
manner. For this purpose we developed equivalent fluorescent
probes to visualize the labeling using SDS/PAGE gel analysis.
Hence, fluorescent compounds 27 and 28, in which the fluoro-
phore lissamine has been introduced in place of the biotin
moiety (Figure 1a), were prepared by following similar synthet-
ic routes to the ones above mentioned (see Supporting Infor-
mation for details) and the affinity for their corresponding re-
ceptors was determined (Table 1). As a representative example,
Figure 1b shows that probe 27 was able to label proteins in
a UV irradiation-dependent manner indicating that these inter-
actions reflect noncovalent binding events, as expected for
GPCR ligands.
In addition, the intensity of
the labeling was concentration-
dependent (Figure 1c) and this
binding could be displaced in
variable degrees by an excess of
the high-affinity parent ligand
1 [Ki (5-HT1A)=2.4 nm)] (Fig-
ure 1d). Similar results were ob-
tained with probe 28 (data not
shown). Furthermore, clickable probes 7 and 18 showed a simi-
lar capacity to label proteins in cell homogenates, although
this capability was reduced in whole cells (Supporting Informa-
tion, Figure S1). Together, these results prompted us to use
probes 5 and 16 in a complex proteome to obtain information
about their targets.
Mass spectrometry profiling of ligand-bound proteins
In order to characterize the ligand-bound proteins, we de-
signed a chemical proteomic platform based on biotin-strepta-
vidin affinity followed by MS analysis (Figure 2). We used ho-
mogenates of HEK-293 cells transfected with the receptor
under study as the complex proteome.
Accordingly, membrane homogenates were treated with the
corresponding probe and irradiated with UV light. In order to
Figure 1. Fluorescent probes for serotonin 5-HT1A and 5-HT6 receptors suitable for gel analysis. a) Structure of probes 27 and 28. b) SDS-PAGE analysis of
membranes treated with 5 mm of probe 27 with and without UV irradiation. c) Concentration-dependent labelling of membranes with probe 27 at the indicat-
ed concentrations. d) Labelling with probe 27 (5 mm) in the presence of an excess (500 mm) of the 5-HT1A high-affinity ligand 1. In all cases, samples were irra-
diated at 360 nm for 1 h on ice.
Figure 2. Scheme of the chemical proteomic platform.
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distinguish the proteins that specifically interact with the
probe, multiple control samples were carried out in parallel, in-
cluding proteomes treated with the probe in the presence of
an excess of a high-affinity ligand as competitor, and pro-
teomes to which no probe was added. The probe-labeled pro-
teins were enriched by binding to streptavidin-conjugated
beads, subjected to on-bead trypsin digestion, and subse-
quently identified by multidimensional LC separation and MS–
MS analysis (see the Supporting Information). Specific targets
of the probes were identified by filtering the data for proteins
that were present in the probe-treated samples and absent in
the control samples (Supporting Information, Tables S1 and
S2). Under these conditions, 30 proteins were identified with
probe 5 and 12 with probe 16. It is important to note that
both probes 5 and 16 were able to capture their cognate pri-
mary receptors 5-HT1A and 5-HT6, respectively. This result sup-
ports the solidness of the chemoproteomic platform. We then
performed an analysis based on gene ontology (GO) annota-
tions (protein class, cellular localization, biological process, mo-
lecular function and signaling pathways) within our data set
using the protein analysis through evolutionary relationships
(PANTHER) classification system,[15] which includes both experi-
mental data and bioinformatics algorithms. This analysis re-
vealed that proteins targeted by probes 5 and 16 (black and
white bars, respectively, Figure 3a) belong to a variety of func-
tional classes. With respect to the cellular component, a notable
enrichment in mitochondrial proteins was observed for both
probes (Figure 3b). Searching for biological process and molec-
ular function trends (Figure 3c and 3d, respectively), we dis-
covered significant enrichments in proteins related to fatty
Figure 3. Analysis of gene ontology (GO) terms. a) Protein classes identified with probe 5 (in black) and 16 (white) expressed as percentage of the total identi-
fied proteins. b) Specific enrichment in mitochondrial proteins. Black bars represent the number of mitochondrial proteins identified and grey bars the expect-
ed number according to the PANTHER database (***, p<0.001). c) Involvement of identified proteins in specific biological processes (in black are shown
those identified with probe 5 and in white those identified with probe 16). The right panel shows the enrichment in specific processes (black bars represent
the number of identified proteins and grey bars the expected number according to the PANTHER database; *, p<0.05; ***, p<0.001). d) Classification of
identified proteins based on their molecular function (in black are shown those identified with probe 5 and in white those identified with probe 16). e) In-
volvement of identified proteins in specific signaling pathways.
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acid oxidation, cellular metabolic processes, and protein fold-
ing for probe 5, while for probe 16 protein folding is the bio-
logical process mainly affected (Figure 3c, right panel). This
result is in agreement with the chaperones targeted by the
two probes. In particular, HSP60, HSP70, HSP75, and HSP90,
are captured with probe 5 (Supporting Information, see
Table S1), and HSP70, HSP90, and prohibitin (PHB) with probe
16 (Supporting Information, Table S2). Then, we analyzed the
signaling pathways affected by these two probes (Figure 3e).
As expected, signaling pathways corresponding to the activa-
tion of the 5-HT1A and 5-HT6 GPCRs were identified (blue sec-
tors in Figure 3e). In addition, signaling pathways related with
cancer were also uncovered for both probes (red sectors). Re-
markably, pathways related to Alzheimer (AD), Huntington
(HD), and Parkinson (PD) diseases emerged for probe 16
(purple sector in Figure 3e, right chart). Taking a closer look at
these results, and using the Database for Annotation, Visualiza-
tion, and Integrated Discovery (DAVID)[16] and the implemented
KEGG pathway maps,[17] we were able to further explore the
identified proteins. This analysis revealed that some of the tar-
geted mitochondrial proteins have been related to these neu-
rodegenerative diseases. Substantial evidence supports the in-
volvement of mitochondrial dysfunction in the pathogenesis of
these disorders.[18] Specifically, heat-shock proteins (HSPs) have
been proposed as therapeutic targets to reduce the neurode-
generation caused by protein aggregation[18a] and the voltage-
dependent anion channel (VDAC) is currently under consider-
ation as a therapeutic target for AD.[19] Moreover, ATP synthase
and prohibitin have been linked to AD and PD.[20] In addition
to the important role of these proteins for neurodegenerative
diseases, the HSP family of proteins has received a growing at-
tention given their potential as antitumor targets.[21]
Hit validation
Hence, at this point it was important to validate some of these
hits, that is, to confirm whether the probe and the parent
ligand recognize in a direct manner the identified proteins.
Among them, HSP60 and prohibitin were chosen for further
validation. Our results show that HSP60 is recognized by the
fluorescent probe 27 (Figure 4a) and this binding is displaced
by a 100-fold excess of the nonlabeled high-affinity ligand
1 (Figure 4b). In addition, to fully explore the versatility of the
approach, clickable probe 7 was used and, after copper-cata-
lyzed cycloaddition with the rhodamine–biotin–azide deriva-
tive (TriN3,
[22] see the Supporting Information for details), simi-
lar results were obtained (Figure 4c). Also, a specific recogni-
tion of HSP60 could be observed in the context of a complex
proteome in which exogenous HSP60 is added (Figure 4d). We
further extended our validation to prohibitin protein with
probe 28 and with the alkyne-tagged compound 18, as shown
in Figure 4e,f. As expected, the recognition of HSP60 and pro-
hibitin disappears if the proteins are denatured by heating
prior to labeling (Supporting Information, Figure S2), a fact
that supports the specificity of the binding.
Encouraged by these results, we further assessed that HSP60
was a bona fide target of the parent serotonin receptor ligand
1. Indeed, a functional assay showed that this compound, at
concentrations of 10 mm, reduced by 25% the ATPase activity
of HSP60 (Figure 5a).&&ok?&& This inhibition is dose-de-
pendent (Supporting Information, Figure S3) with an IC50 value
of 63 mm. We next sought to confirm these results in a cellular
context. Towards this aim, we selected two cell lines that ex-
press HSP60 (Figure 5b) and whose survival is significantly
regulated by this protein, the breast cancer cell lines MCF-7
and MDA-MB-231.[23] Remarkably, compound 1 induces cyto-
toxicity in both cell lines (Figure 5c) with an IC50 value of
12 mm in MCF-7 cells and 63 mm in MDA-MB-231 cells.
HSP60 is a chaperone protein that has been related to
cancer and CNS disorders.[21,24] However, its potential as a drug
target has not been widely explored because of a lack of inhib-
itors. They are basically restricted to two nucleoside deriva-
tives, one natural product and one carboranyl derivative.[21,25, 26]
Figure 4. In-gel validation of HSP60 and prohibitin as hits of the 5-HT1A- and
of the 5-HT6R-directed ligands, respectively. a) Probe 27 labels HSP60 in
a dose-dependent manner. b) The labeling of HSP60 with probe 27 (2 mm)
can be displaced with an excess (100-fold) of the 5-HT1A high-affinity ligand
1. c) Clickable probe 7 (10 mm) labels HSP60 in a specific manner. d) Probe
27 labels HSP60 in a complex proteome. e) Probe 28 labels prohibitin (fluo-
rescence upper and coomassie bottom) at 10 mm. This labeling can be dis-
placed with an excess (25-fold) of the 5-HT6 high-affinity ligand 14. f) Clicka-
ble probe 18 (10 mm) labels prohibitin and can be displaced with an excess
of the 5-HT6 high-affinity ligand 14.
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Hence, the serotonin ligand 1 could represent a new structural
scaffold for the development of novel HSP60 ligands. Together,
these results support that the described probes are not only
able to capture the GPCR they were originally designed for,
but also can aid the identification of additional targets of the
ligands, in this case other targets related to neurodegenerative
diseases (VDAC, ATP synthase or chaperones as the HSPs or
PHB) or cancer (such as HSPs, PHB or ANT2[27] ; Figure 6).
Conclusions
In this work we have developed a new set of probes suitable
for the nonbiased study of off-targets of 5-HT1A and 5-HT6 re-
ceptor ligands. The protein profiling has revealed additional
targets of these ligands some of which have been validated.
Among the identified hits, a set of specific mitochondrial pro-
teins related to neurodegenerative diseases and cancer stands
out, as they could represent additional targets of the studied
ligands. In particular, the chaperone HSP60 has been identified
as a bona fide target of the studied 5-HT1A receptor ligand and
the biological relevance of this binding has been validated in
a cellular context. To the best of our knowledge, these probes
are the first tools suitable for the study of serotonin GPCRs by
chemoproteomic methods, and further insights on the identi-
fied hits are currently under investigation in our laboratory.
This approach could be extended to other drugs of interest to
study the proteome expressed in disease-relevant systems.
Experimental Section
Compound synthesis
Unless stated otherwise, starting materials, reagents, and solvents
were purchased as high-grade commercial products from Sigma–
Aldrich, Acros, ABCR, Bachem, Fluorochem, Scharlab, or Panreac,
and were used without further purification. Dichloromethane was
freshly distilled from calcium hydride. THF and diethyl ether were
freshly distilled from sodium and benzophenone. All nonaqueous
reactions were performed under an argon atmosphere in oven-
dried glassware. Full details regarding the synthetic procedures
and characterization data of all compounds are given in the Sup-
porting Information. Spectroscopic data of all described com-
pounds were consistent with the proposed structures. Elemental
analyses (C, H, N, S) were within 0.5% of the calculated values, con-
firming a purity of at least 95% for all tested compounds.
Binding assays
Membranes from HEK-293-EBNA (5-HT1AR) and HEK-293 (5-HT6R)
cells expressing the indicated human receptors were purchased
from Perkin–Elmer and conserved at 80 8C in packaging buffer
for subsequent use. Competitive inhibition assays were performed
as previously described.[13,28] Ki values are expressed as the average
and standard error obtained from three independent experiments
carried out in triplicate.
Gel profiling of cell membranes
Membranes of cells expressing the corresponding human receptor
(Perkin–Elmer) were homogenized in the appropriate buffer and in-
cubated in the absence or presence of the probe in 96-well poly-
styrene plates (see the Supporting Information for full details).
After incubation at 37 8C for 30 min, samples were irradiated at
360 nm using an UV lamp on ice for 1 h. Then, a 5% b-mercaptoe-
thanol solution in Laemmli loading buffer (BioRad) was added and
the samples were completely solubilized by heating at 80 8C for
10 min. Aliquots of each sample were loaded and resolved with
10% SDS-PAGE gels and fluorescence images were obtained with
a Typhoon 9400 scanner.
Mass spectrometry profiling of ligand-binding proteins
Membrane homogenates were incubated in the absence or pres-
ence of the probe in a final volume of 600 mL of incubation buffer
in a 24-well polystyrene plate (see the Supporting Information for
full details). After incubation at 37 8C for 30 min, samples were irra-
Figure 5. Enzyme and cellular effects of serotonin 5-HT1A ligand 1. a) Inhibi-
tion of recombinant HSP60 ATPase activity by compound 1 (10 mm). b) Rep-
resentative gel showing the expression of HSP60 in MCF-7 and MDA-MB-231
cells. Equal amounts of cell lysates (25 mg) were immunoblotted with
a mouse anti-HSP60 and the corresponding band (60 kDa) is marked with
the double-arrowhead. c) Compound 1 induces cell cytotoxicity in a dose-
dependent manner. Data correspond to the average  s.e.m. of two to three
independent experiments performed in duplicate or triplicate. *, P<0.05; **,
P<0.01 (vs. vehicle-treated samples) by the Student’s t test.
Figure 6. Schematic representation of the proteins targeted by probes 5 and
16 and their involvement in different pathologies.
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diated as indicated above, and transferred to microtubes. Proteins
were incubated with streptavidin-agarose beads (Pierce) for 12 h at
4 8C, transferred to falcon tubes, and the beads were processed as
detailed in the Supporting Information. For MS analysis, proteins
from pull-down samples were loaded onto SDS-PAGE and run in
an unique band that concentrated all the proteins in the sample,
stained with Coomassie Brilliant Blue G-250 and excised in 1 mm3
small pieces, which were washed in ultrapure H2O. Samples were
subjected to reduction and alkylation, and in-gel digested over-
night at 37 8C by adding modified porcine trypsin (Promega) at
a final ratio of 1:20 (trypsin/protein). After digestion, peptides were
vacuum-dried and finally dissolved in 0.1% formic acid for LCMS/
MS analysis. The tryptic peptide mixtures were subjected to nanoli-
quid chromatography coupled to MS for protein identification as
detailed in the Supporting Information.
In-gel hit validation
Pure HSP60 (2 mg) or prohibitin (1 mg) were incubated in the ab-
sence or presence of the corresponding probe and treated as de-
scribed above. For click chemistry reactions followed by SDS/PAGE
experiments, pure protein (2 mL of a 1 mgmL1 in PBS) was incu-
bated in the absence or presence of probe 7 (10 mm) or 18 (10 mm)
in a final volume of 45 mL of PBS in a 96-well polystyrene plate
(45 mL reactions were set up so that, once the cycloaddition re-
agents were added, the total reaction volume is 50 mL). After incu-
bation at 37 8C for 30 min, samples were irradiated as described
above, transferred to microtubes (eppendorf), and the click chemis-
try reaction was carried out using the reagents and concentrations
detailed in the Supporting Information. Finally, aliquots of each
sample were loaded and resolved with 10% SDS-PAGE gels. Fluo-
rescence images were obtained with a Typhoon 9400 scanner.
HSP60 ATPase assay
Human recombinant HSP60 (Enzo Life Sciences) was incubated in
the presence or absence of the compound under study using the
conditions previously described[26] and ATP content was deter-
mined using the ATP assay kit from Abcam.
Cell culture, immunoblot analysis of HSP60 and cytotoxicity
assays
Cells were routinely incubated at 37 8C with 5% CO2 and grown in
Dulbecco’s modified Eagle’s medium (Gibco) containing 10% heat-
inactivated fetal bovine serum (FBS), 1% l-glutamine, 1% sodium
pyruvate, 50 U/mL penicillin, and 50 mgmL1 streptomycin (Gibco).
The expression of HSP60 was determined by immunoblot analysis
using a mouse anti-HSP60 (BD Transduction) as the primary anti-
body following the conditions previously reported.[29,30] Cell viabili-
ty was determined using a standard colorimetric assay based on
the metabolism of the 3-(4,5-dimethyl-1,3-thiazol-2-yl)-2,5-diphen-
yl-2H-tetrazol-3-ium bromide (MTT) salt by the viable cells as previ-
ously described.[29–30]
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